Carl read the papersWhat it actually is
Cerebrolysin is not one peptide. It is a purified extract of pig brain, a mixture of low-molecular-weight peptides and free amino acids, sold in ampoules by the Austrian company EVER Neuro Pharma. Each mL holds 215.2 mg of the concentrate.
It is a licensed prescription medicine in a number of countries (Austria, Russia and Croatia among them) and is widely used for stroke in Russia, Eastern Europe, China and other parts of Asia. It is not approved in the US. One practical point before anything else: it is made from pig brain, which rules it out for anyone who avoids pork-derived products.
How it’s thought to work
- Multi-modal neuropeptide — The maker describes it as a mixture that supports the brain's own repair processes. As a mixture it has no single receptor or single active ingredient to point at, which is the core difficulty in studying it.
- Neuroprotection — The theory is that it limits damage in the days after a stroke or brain injury. The Cochrane reviewers call its neuroprotective properties potential, which is the right word.
- Neurorecovery with rehab — In the stroke recovery trials it is given alongside a rehabilitation programme, never instead of one. The claim is that it makes the rehab work better.
- Course-based dosing — Given daily by drip or injection for a few weeks, then stopped, with repeat courses months later. It is not a daily-forever drug.
What the research says
Two stories here, and they are not measuring the same thing. Trials run with the manufacturer involved report better recovery: CARS found a large benefit on arm function at day 90 when 30 mL a day for 21 days was added to stroke rehab, and the CAPTAIN brain-injury trials (185 people) found a small-to-medium benefit. But the maker's own biggest stroke trial, CASTA (1,070 people), missed its main endpoint. The independent Cochrane review (2023) pooled seven trials and 1,773 people (one trial used Cortexin, a cattle-brain cousin) and found it probably makes little or no difference to death after acute stroke, with a possible rise in non-fatal serious adverse events (risk ratio 2.39). A 2021 European guideline on early stroke rehab still recommends it; several of its authors also wrote CARS. All of this is in patients with stroke, brain injury or dementia, which is not the same thing as a healthy person chasing focus.
- CARS (stroke rehab, maker's staff among the authors): large benefit on arm function at day 90 with 30 mL a day for 21 days.
- CASTA (1,070 people, acute stroke, sponsored by the maker): no difference on the main endpoint; a better trend in severe strokes was a post hoc finding.
- Cochrane 2023 (7 trials, 1,773 people): little or no effect on death; more non-fatal serious adverse events (risk ratio 2.39, moderate certainty).
- CAPTAIN brain-injury meta-analysis (185 people): small-to-medium benefit at days 30 and 90.
- Dementia: Cochrane rates the vascular dementia evidence weak with high risk of bias; a 2015 Alzheimer's meta-analysis of six trials, two of whose authors also wrote CARS, is more positive.
Reported protocols
These are the doses the peptide community actually reports running (Reddit & forums), alongside published research — logged for education, not as a recommendation to use.
| Parameter | Commonly reported range |
|---|---|
| Label dose | Stroke: 20-50 mL a day by IV drip for 10-21 days. Brain injury: 20-50 mL a day for 7-30 days. Prescription medicine (Austrian label, as published by the maker). |
| Label dose (dementia) | 10-30 mL a day, 5 days a week for 4 weeks, repeated 2-4 times a year |
| Route limits | Into the muscle up to 5 mL; straight into a vein up to 10 mL, slowly; 10-50 mL only as a diluted drip |
| Trial doses | Stroke trials: 30 mL a day by IV drip for 10 days (CASTA) or 21 days (CARS). Brain-injury trials: 50 mL a day for 10 days, then two more 10-day rounds at 10 mL. |
| Community dose | The one independent self-user report found (an MS patient on a patient forum) describes 5 mL into the muscle about five days a week, in cycles with breaks of weeks between them. That is the label's ceiling for a muscle injection, not a gentle starter dose, and one report is not a protocol. |
| Community tip | The same report describes overstimulation around week four (talking too much, getting irritable) and short-lived chills early in each cycle, which is why breaks went in. The label lists agitation and insomnia too, and it is built around courses, not daily use. |
Common use cases
| Goal | Community protocol notes |
|---|---|
| Early stroke rehab (in hospital) | the use with the most trial data and a European guideline behind it |
| Moderate to severe brain injury | CAPTAIN trials, small-to-medium effect, prescribed and supervised |
| Dementia courses | repeated 4-week courses where licensed; evidence rated weak |
| Self-directed nootropic use | the online use; not what any of the trials studied |
Mixing it (reconstitution)
Freeze-dried peptides must be reconstituted with bacteriostatic water before they can be measured. Carl’s calculator turns “mg in the vial + ml of water + target dose” into “units on the syringe” — and tells you how long the vial lasts.
→ Open the Reconstitution Calculator
Injection & handling
This is a hospital drug and the label is written for one. Up to 5 mL can go into the muscle and up to 10 mL straight into a vein, injected slowly over about 3 minutes; 10 to 50 mL is diluted to at least 100 mL and run as a drip over about 15 minutes. Injecting too fast is linked to dizziness, sweating and a hot feeling, and very rarely to palpitations or arrhythmia. Ampoules are used straight after opening. The maker's prescribing summary rules it out in epilepsy, severe kidney impairment and allergy to any of its parts; the Russian label narrows the epilepsy rule to status epilepticus and asks for caution with any seizure disorder or a history of allergies.
Stacks it appears in
- With rehab — The pairing the trials actually tested. The drug was always given alongside a rehabilitation programme, not as a stand-in for one.
- With Semax — Both turn up in the same brain-recovery and focus conversations. No published trial has tested them together.
Sources
- Ziganshina LE et al. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev 2023
- Muresanu DF et al. Cerebrolysin and Recovery After Stroke (CARS). Stroke 2016
- Heiss WD et al. Cerebrolysin in acute ischemic stroke in Asia (CASTA). Stroke 2012
- ClinicalTrials.gov NCT00868283: Safety and Efficacy of Cerebrolysin in Acute Ischemic Stroke (CASTA)
- Vester JC et al. Cerebrolysin after moderate to severe TBI: CAPTAIN meta-analysis. Neurol Sci 2021
- Cui S et al. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev 2019
- Gauthier S et al. Cerebrolysin in mild-to-moderate Alzheimer's disease: meta-analysis. Dement Geriatr Cogn Disord 2015
- Beghi E et al. EAN/EFNR guideline on pharmacological support in early motor rehabilitation after stroke. Eur J Neurol 2021
- Trimmel H et al. Life-threatening anaphylaxis due to Cerebrolysin. Case Rep Neurol Med 2024
- EVER Neuro Pharma: Cerebrolysin administration and dosage
- EVER Neuro Pharma: About Cerebrolysin
- Vidal.ru: Cerebrolysin (Russian label)
- HALMED (Croatia): Cerebrolysin marketing authorisation
- SAHPRA: Peptide Products - Public Information (May 2026)
- WADA 2026 Prohibited List
